Type 2 Diabetes Treatment - Part 6 - SGLT2 Inhibitors

from Hospital and Internal Medicine Podcast · host Gil Porat, M.D., FACP, CPT

Sodium-Glucose Transporter 2 Inhibitors decrease glucose re-absorbtion. The diuretic effect, weight loss, DKA, cardiac outcomes, blood pressure, genital infections and a whole bunch of other information is discussed. SGLT2s include Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertagliflozin (Steglatro), with more to be released in the future.

Episode metadata supplied by the publisher feed · Published Sep 26, 2018

Embed this episode

Attribution link and audio player

NOW PLAYING

Type 2 Diabetes Treatment - Part 6 - SGLT2 Inhibitors

0:00 20:05

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Hospital and Internal Medicine Podcast?

This episode is 20 minutes long.

When was this Hospital and Internal Medicine Podcast episode published?

This episode was published on September 26, 2018.

Can I download this Hospital and Internal Medicine Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!